Introduction
Before the identification of Mendelian cancer susceptibility genes, the low relative risks seen in relatives of cancer patients were mistakenly believed to be inconsistent with large effects of mutations in single genes (Anderson, 1974) . The modest familial risks seen in firstdegree relatives of patients are in fact compatible with Mendelian predisposition, and the genetic effect must be substantial. For a dominant gene to cause a relative risk of 2 in patients' siblings, the risk in susceptible individuals has to be at least 10 times greater than in nonsusceptibles, and for a recessive gene the risk ratio must be over 20 (Peto, 1980) .
Over the last two decades, research on inherited cancer susceptibility has focused on the identification of mutations segregating with disease in large families. Genetic linkage analysis has led to localization of highly penetrant genes for several common cancers, including breast and ovarian cancers (BRCA1 and BRCA2 on chromosomes 17 and 13) (Hall et al., 1990; Wooster et al., 1994) , colon cancer with adenomatous polyposis coli (APC on chromosome 5) (Bodmer et al., 1987) , HNPCC (the mismatch repair genes MSH2 and MLH1 on chromosomes 2 and 3), (Lindbolm et al., 1993; Peltomaki et al., 1993) , melanoma (CDNK2A on chromosome 9) (Cannon- Albright et al., 1992) , and testicular cancer (TCG1 on the X chromosome) (Rapley et al., 2000) .
The growing interest in low-penetrance susceptibility alleles
The discovery that highly penetrant genes account for most large breast cancer families but only a minority of families with two or three cases (Ford et al., 1998) confirmed the suggestion that less penetrant genes may make a substantial contribution to the overall breast cancer incidence (Peto et al., 1996) . Twin studies indicate that much of the familial aggregation of cancer results from inherited susceptibility (Lichtenstein et al., 2000) , especially in breast cancer (Peto and Mack, 2000) . Highly penetrant mutations in known genes cannot account for most of the excess risk (Figure 1 ). Mutations in known predisposition genes, including BRCA1 and BRCA2, account for only about 20% of the twofold excess in breast cancer patients' relatives (Anglian Breast Cancer Study Group, 2000) . Similarly, while about 5% of colorectal cancers can be ascribed to germline mutations in APC, MLH1 or MSH2, the majority of the excess familial risk remains unaccounted for (Figure 1 ). The remaining familial risk could be due to high-penetrance mutations in as yet unidentified genes, but multiple-case cancer families have failed to reveal significant linkage to novel loci in recent studies, and a polygenic mechanism now appears more plausible, at least for breast cancer (Peto, 2002; Pharoah et al., 2002) . Under the polygenic model, a large number of alleles each conferring a small genotypic risk (perhaps of the order of 1.5-2.0) combine additively or multiplicatively to confer a range of susceptibilities in the population. More than 100 such polygenes may contribute to susceptibility (Table 1) . Individuals carrying few such alleles would be at reduced risk while those with many might suffer a lifetime risk as high as 50%. Segregation analysis suggests that half of all breast cancers may arise within the most susceptible 12% of the population (Pharoah et al., 2002) . If low-penetrance alleles cause a substantial proportion of this genetic susceptibility, their identification is of great practical importance.
Types of sequence change that act as low-penetrance alleles
Most Mendelian cancer predisposition genes act in a cell-autonomous fashion. Mendelian diseases or traits that are not caused by deletions are usually due to alterations in exons, but other changes such as those in promoter sequences may sometimes affect susceptibility. Many polygenes will probably have cell-autonomous effects, but some will act globally, including carcinogen metabolism polymorphisms (e.g. CYP1A1, GSTM1, GSTT1, NAT1 and NAT2) and antitumour immune response genes (e.g. TNF1a and TNF1b). Others will affect the local tumour environment, particularly through epithelial interactions (e.g. APOE and PLA-GA2), or act within the cell either metabolically (e.g. MTHFR) or through DNA repair or genomic stability (e.g. MSH2, MLH1, MSH6, CHEK2, BRCA1, BRCA2 and BUB1). A significant part of the polygenic contribution to low-penetrance susceptibility may be derived from nonconservative missense mutations (or a restricted set of protein-truncating variants) in evolutionarily conserved domains. Some, such as I1307K in APC, will be in classical tumour-suppressor genes, but any gene with a function relevant to any aspect of carcinogenesis is a strong candidate as a low-penetrance susceptibility allele. Some polymorphisms will have a direct functional effect, but a single-nucleotide polymorphism (SNP) may be associated with susceptibility through linkage disequilibrium with a functional variant. The choice of candidate low-penetrance genes will inevitably be based on current knowledge of cancer biology, but it is likely that as yet unidentified pathways also influence tumour development. Some alleles affect different components of the same pathway. For example, germline mutations in ATM, BRCA1 and BRCA2, which confer an increased risk of breast cancer, are all involved in DNA double-strand break repair and DNA damageinduced checkpoint activation (Dasika et al., 1999) .
Linkage versus association
Dominantly acting alleles that increase cancer incidence by twofold or less will rarely cause multiple-case families and are therefore difficult or impossible to identify through linkage (Risch and Merikangas, 1996) . The search for low-penetrance alleles has centred increasingly on association studies, where the frequencies of candidate alleles are compared in cases and controls, either directly or using the transmission disequilibrium test (TDT) or allied tests. To detect a gene with frequency 0.1, conferring a twofold increase in risk by linkage would require about 10 000 affected sibling pairs. In contrast, it should be detectable through association with only 500 unselected cases and 500 controls.
There are a number of methods of estimating the risk associated with a specific variant. For dominant biallelic sequence changes, carrier frequencies in cases and controls can be used to derive an odds ratio. This approach is, however, less powerful for co-dominant effects than a comparison of frequencies of the three genotypes among cases and controls using homozygosity of the 'wild-type allele' as the reference group. Where homozygotes are rare heterozygotes and homozygotes are often analysed together, but this is only efficient if a dominant model can be presumed. Similarly, combining heterozygotes with wild-type homozygotes is only appropriate if alleles act recessively. For multiallelic loci, the frequency of certain genotypes can be low and the w 2 statistics for such comparisons do not conform well to the asymptotic distribution. It is therefore Lower figure is based on the assumption that alleles interact multiplicatively (i.e. the penetrance of the disease is the product of the penetrances contributed by two or more loci), upper figure assumes that alleles interact additively (i.e. the penetrance of the disease is represented by the sum of the penetrances contributed by two or more loci) common practice to group alleles and analyse them together as a bi-allelic polymorphism.
How many low-risk alleles have been identified?
The last 10 years have seen a dramatic rise in the number of published studies reporting the relationship between SNPs in candidate genes and the risk of cancer. Despite this considerable effort, however, few disease loci have been identified unequivocally. Published systematic reviews on specific polymorphisms and risk of breast (Dunning et al., 1999) and colorectal (Houlston and Tomlinson, 2001 ) cancers illustrate this apparent failure (Table 2 ). In a review of 50 studies of the effects of common alleles of 13 genes on risk of colorectal cancer 16 significant associations (Po0.05) were seen, but only three were reported in more than one study. The only significant associations in the pooled data were for APC-I1307K, HRAS1-VNTR and MTHFR Val/Val . A systematic review of 46 studies on the effects on breast cancer risk of 18 different genes revealed 12 statistically significant associations. None was reported in more than one study, and the pooled analysis gave a significant difference in genotype frequency for only three SNPs: CYP19-(TTTA)10, GSTP1-Ile105Val and TP53-Arg72Pro. Table 2 summarizes these findings, together with results of metaanalyses of the risks of lung, bladder and prostate cancers associated with selected SNPs. For many of these candidate genes, there was little prior evidence of involvement of the specific locus and the associated P-values should in principle be adjusted by Bayesian methods, using prior probabilities based on the strength of the evidence that they are involved in cancer aetiology or that the specific type of germline variation affects the structure or level of the expressed protein.
Statistical power and multiple testing
Most studies have inadequate statistical power to detect the weak associations that low-penetrance alleles are likely to confer. Fewer than 40% of the studies reviewed Ntais et al (2003) by Houlston and Tomlinson (2001) and Dunning et al. (1999) had 80% or greater power to detect a twofold difference in risk at the 0.05 significance level. The analysis of large numbers of polymorphisms also raises the problem of multiple testing, which further erodes statistical power. In a genome-wide search for a highrisk susceptibility allele, the stringent significance criterion of Po10 À7 at each putative locus has been advocated to guarantee posterior odds of less than 20 : 1, as the clinical consequences of incorrect identification are potentially serious. In contrast, the clinical aim of identifying low penetrance polygenes is to classify individuals on the basis of the total number of high-or low-risk alleles that they carry. A less extreme significance level at each locus is therefore appropriate, as inclusion of a few incorrectly identified genes is clinically less important than failure to detect a substantial proportion of disease-causing alleles.
Using cases with affected relatives
Analysis of unselected cases is satisfactory for the evaluation of common alleles but has limited power if the carrier frequency is less than 5%. Restricting the study to early-onset cases or pathologically defined subsets might increase the power, but in the absence of good evidence for a different genetic basis in younger patients or in those with a particular histology such restrictions on eligibility may merely reduce the available sample size. The power of association studies can, however, be significantly enhanced by cases selected for a family history of cancer. Houlston and Peto (2003) calculated the power of association studies based on unselected and familial cases (Figure 2 ). Assuming two controls per case, a dominant allele conferring a relative risk of 2.0 carried by 5% of the population would be detectable using 800 unselected cases. If the prevalence were only 1% in controls, however, 3700 unselected cases would be required. In contrast, if the cases analysed had two affected relatives the number required would be reduced from 3700 to 700, a more than fivefold reduction in laboratory costs. Bilateral breast cancer patients should prove particularly informative. They can be identified systematically through cancer registries, yet they are as powerful as cases with two affected relatives (Antoniou and Easton, 2003) .
The potential of association studies of familial cases to detect rare susceptibility alleles conferring a relative risk of less than 2.0 is illustrated by the CHEK2 1100delC mutation in breast cancer patients. This allele, which is carried by B1% of the population, confers a 1.7-fold increase in breast cancer risk (Meijers-Heijboer et al., 2002) . The prevalence was not significantly increased among unselected breast cancer cases (1.4%), but was greatly increased among familial cases not carrying BRCA1 or BRCA2 mutations (5.1%; Po10
À7
). The relative risk in pooled data on unselected cases was 2.3 (CHEK2 Breast Cancer Consortium, 2004).
Population stratification
Population stratification, where a regionally or ethnically defined subgroup has a different risk of cancer, can result in spurious associations between disease and arbitrary genetic markers. The potentially confounding effect of population stratification should in principle be allowed for in the design and analysis of a study. One method of circumventing the problem is to use familybased controls. The most common approach is the transmission disequilibrium test, which assesses the evidence for preferential transmission of one allele over the other from heterozygous parents. Allied statistics based only on sibling genotypes have been devised to obviate the requirement for parental genotypes. Such restrictions on eligibility inevitably lead to smaller studies. These tests are also inherently less powerful than conventional case-control methods (Risch and Teng, 1998) . Population stratification remains a potential problem, but its effects within large studies have been rather exaggerated and can usually be assessed by suitable analysis. If cases and controls are well matched, differences in the frequency of genotypes will only be seen at predisposition loci. Stratification can therefore be detected by typing a series of unlinked markers chosen from a panel known to exhibit differences in allele frequency between populations. Stratification operates globally across the whole genome, whereas linkage disequilibrium operates locally over short genetic distances (Pritchard et al., 2000) .
Incorporating covariates
Some SNPs will affect the risk more strongly in the presence of other genes or environmental influences. An example of such a gene-environment interaction is provided by the common C677T variant in methylenetetrahydrofolate reductase (MTHFR), which leads to disturbed folate metabolism and decreased genomic DNA methylation. A number of studies have reported an association with overall cancer risk, and in a Figure 2 Number of cancer patients required to detect a susceptibility allele conferring a multiplicative relative risk of 2, with one control per case (90% power at P ¼ 0.01) prospective study the effect was substantially greater in those with lower circulating levels of folate (Heijmans et al., 2003) . For a given sample size, strength of interaction and allele frequency, the gain in power achieved by allowing for the interaction depends on the magnitude of the exposure frequency.
Genome-wide searches -haplotype or candidate allele analysis?
Almost all studies reported to date have evaluated only one or two SNPs at each candidate locus, but in future high-density systematic searches will define haplotypes throughout the genome. Defining haplotypes can be problematic, but for certain loci it is unambiguous. For example, a four-site haplotype spanning 28 kb effectively encompasses catechol-O-methyl transferase (COMT) (DeMille et al., 2002) . The overall linkage disequilibrium for the COMT haplotype is strong and significant in population samples from around the world, and only two or three SNPs are required to define it.
SNP microarrays and other analytical platforms capable of high-throughput SNP genotyping will make genomewide association studies feasible within the next few years. High marker density is essential for haplotype association studies, since the power of an association test declines rapidly as linkage disequilibrium diminishes. The extent of linkage disequilibrium varies significantly between regions of the genome. Computer simulations assuming a panmictic population suggest that linkage disequilibrium may only extend B3 kb in some regions of the human genome (Kruglyak, 1999) . Direct observation shows that detectable linkage disequilibrium extends over distances that are rarely less than 5 kb (Dunning et al., 2000) , typically B50-60 kb (Abecasis et al., 2000; Reich et al., 2001 ) and occasionally several hundred kb (Abecasis et al., 2000; Collins et al., 2001; Morton et al., 2001) . The number of SNPs required for reliable haplotype identification is thus at least 10 6 . Comparing haplotype frequencies in cases and controls can be more powerful than analysis of single alleles in populations in which an individual founder mutation such as BRCA1-185delAG or APC-I1307K in Ashkenazi Jews accounts for a substantial percentage of all cases, or in any population for a susceptibility allele in a region of very low recombination. In panmictic populations, however, analysis of SNPs that define relevant allelic variants may be needed to identify the majority of low-penetrance alleles (Botstein and Risch, 2003) . At present, a genome-wide search should include the 50-100 000 of the B10M known SNPs within the genome that map to coding regions. In future, however, selection of candidate SNPs at relevant loci will be determined by their predicted effects on structure and function based on the human genome sequence. Some relevant SNPs will be identified by resequencing candidate genes, but in the longer term SNPs at loci identified by structural considerations in genes of unknown function may well prove more productive. Large-scale high-throughput resequencing will be required to identify the rare pathogenic variants that may constitute the majority of lowpenetrance alleles. In Mendelian diseases for which the underlying mutation has been identified, the majority (59%) are missense, including SNPs in nonsense codons, 22% are deletions, 10% are splice site mutations and 7% are insertions or duplications (Botstein and Risch, 2003) . Less than 1% are in regulatory regions. The latter may be under-reported for methodological reasons, and the spectrum is unlikely to be the same for low-penetrance alleles. Nonetheless, these data suggest that many lowpenetrance alleles are likely to be in-frame changes in coding sequences.
Whichever technology becomes the dominant analytical platform, the cost of extensive SNP typing is likely to remain high, at least in the medium term. Analysing pooled DNA samples significantly reduces costs, but this limits detection of recessively acting alleles and prevents haplotyping. Irrespective of strategy, however, rare variants such as the 1100delC variant of CHEK2 are unlikely to be found by typing arbitrarily selected SNPs in a genome-wide screen even in regions of strong linkage disequilibrium.
Concluding remarks
Around 30 years ago, Anderson (1974) stated that the 2-3-fold excess seen in first-degree relatives of cancer patients 'is not indicative of strong genetic effects. They are more suggestive of the involvement of many genes with small effects acting in concert with environmental or nongenetic factors with larger and more important effects'. This was a statistical fallacy (Peto, 1980) , but there is growing evidence that the conclusion is correct for the majority of breast cancers and perhaps for many other common cancers. The epidemiological evidence is now supported by the discovery of low-penetrance genes that predispose to common cancers. Although the risks associated with each allele may be individually modest, they are likely in combination to contribute a substantial proportion of overall cancer incidence, and considerably more than the high-penetrance genes so far identified. An important feature of the polygenic model is that most susceptible individuals are at elevated risk because of the combined effects of several susceptibility alleles; so until a large number of the relevant alleles have been identified this susceptible group cannot be targeted for earlier screening or prophylactic therapy.
